

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Fumitoshi Asai et al.

Group Art Unit: 1614

Serial No.: 10/600,266

Examiner: Brian Yong S. Kwon

Filed: June 20, 2003

Confirmation No.: 7488

For: Medicinal Compositions Containing Aspirin

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

This Supplemental Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO-SB08, a copy of which is enclosed, are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1.  For each of the following items listed on the enclosed copy of Form PTO-SB08 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed;
2.  For each of the following items listed on the enclosed copy of Form PTO-SB08 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.
3.  Any copy of the items listed on the enclosed copy of Form PTO-SB08 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. \_\_\_, filed \_\_\_\_.
4.  No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:
  - 37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or
  - 37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or

- 37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or
  - 37 C.F.R. §1.97(b)(4) before the mailing date of a first office action after the filing of an RCE under §1.114
5.  No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.
6.  A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):
  - A check in the amount of \$180.00 is enclosed in payment of the fee.
  - Charge the fee to Deposit Account No. 50-3732, Order No. \_\_\_\_\_.
7.  A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:
  - a. one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below; and
  - b. the fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 below.
8.  This Information Disclosure Statement is being filed in compliance with:
  - a.  37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);
  - b.  37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).
  - c.  The fee due under 37 C.F.R. §§1.17(h) is paid as set forth in paragraph 11 below.

9.  I hereby certify that the following item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement:
- Preliminary Opinion of the Opposition Division and Summons to Attend Oral Proceedings Pursuant to Rule 115(1) EPC dated October 7, 2010 for European Patent Application No. 01271850.8
- I hereby certify that none of the following items of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement:
- Office Action dated October 15, 2010 in U.S. Patent Application Serial No. 11/520,168
  - Office Action dated November 5, 2010 in U.S. Patent Application Serial No. 12/006,546
  - Giusti et al., "Response to Antiplatelet Treatment: from Genes to Outcome," [www.thelancet.com](http://www.thelancet.com), August 29, 2010, pp. 1-3
  - Mega et al., "Genetic Variants in ABCB1 and CYP2C19 and Cardiovascular Outcomes after Treatment with Clopidogrel and Prasugrel in the TRITON-TIMI 38 Trial: a Pharmacogenetic Analysis," [www.thelancet.com](http://www.thelancet.com), August 29, 2010, pp. 1-8
10.  This document is accompanied by  a Search Report  Communications which were cited in a corresponding  PCT or  U.S. related patent application.

Also providing list of Related Case U.S patent applications for this case.

11.  A check in the amount of \$ \_\_\_\_\_ is enclosed in payment of the fees due under 37 C.F.R. §§1.17(h) and 1.17(p).
- Charge any fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. 50-3732, Order No. 17620-105003.
- The Commissioner is hereby authorized to charge any fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-3732, Order No. 17620-105003.

Respectfully submitted,  
KING & SPALDING LLP

Dated: November 19, 2010

By:

Margaret B. Brivanlou / Wan Chieh Lee  
Reg. No. 40,922 / Reg. No. 57,297



Correspondence Address:

King & Spalding LLP  
1185 Avenue of the Americas  
New York, NY 10036  
212-556-2100 Telephone  
212-556-2222 Facsimile